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Executive Summary
The Commission to Study Bulk Purchasing of Prescription Drugs and Medical Supplies,
created by Resolve 1999, chapter 75, was established to address the increasing costs of
prescription drugs and the lack of affordable access to insurance coverage for prescription drugs.
The 12-member Commission met four times in October and November 1999, and explored
information and proposals concerning prescription drug costs and expenditures. The Commission
unanimously reached the following recommendations.
1.

The Commission recommends that the State should not at this time
purchasing of prescription drugs as a separate program.

2.

The Commission recommends that the State expand educational outreach to inform
Maine citizens about the many State, Federal and private programs available to reduce
prescription costs.

3.

The Commission recommends that the State investigate the feasibility of joining with
other states, especially in local or regional affiliations, to lower prescription drug costs to
consumers.

4.

Recognizing that the Legislature and the Department of Human Services anticipate that
the Maine Residents Low-Cost Drug Program will reduce prescription drug costs to
consumers, the Commission recommends that the State move forward as rapidly as
possible with the rule-making and legislative process to implement the program.

5.

The Commission recommends that the availability of access to reduced-cost prescription
drugs through the federal Office of Drug Pricing be explored more thoroughly to
determine whether prescription drugs at a lower price can be made more available to
programs providing services to Maine residents.

6.

The Commission recommends that the State encourage a public-private partnership to
generate, maintain and distribute a simple and coordinated therapeutic and pricing
guideline for physicians and other prescribers.

7.

The Commission recommends that the State encourage public-private partnerships for
expanded purchasing volume, thereby increasing consumer’s opportunity to purchase
prescription drugs at lower prices.

8.

The Commission recommends that the Department of Human Services continue to pursue
the Medicaid waiver with the Health Care Financing Administration.

i

pursue bulk
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I

Introduction

A. Inception of the study

During the First Regular Session of the 119th Legislature, the Joint Standing Committee
on Health and Human Services was asked to find ways to address the increasing costs of
prescription drugs and the lack of affordable access to insurance coverage for prescription drugs.
Many legislative proposals made their way to the Committee.
modifications in the Elderly Low-Cost Drug Program.

Several bills advocated

Other bills proposed establishing a

purchasing consortium to make prescription drugs available at lower cost to low-income and
elderly residents of the State. The Committee supported changes to the Elderly Low-Cost Drug
Program (enacted as part of the Budget Bill, PL 1999, c. 401, Part KKK, as amended by PL
1999, c. 531, Part F), and created the Maine Resident Low-Cost Drug Program (PL 1999, c. 431,
see Appendix D). In addition, the Committee recommended and the Legislature approved the
creation of the Commission to Study Bulk Purchasing of Prescription Drugs and Medical
Supplies, referred to in this report as “the Commission,” initially proposed in LD 206 and finally
passed as Resolve 1999, chapter 75.

B. Study charge

The Health and Human Services Committee determined that a comprehensive study of
bulk purchasing of prescription drugs and medical supplies was needed to determine whether bulk
purchasing could be used to provide Maine residents access to affordable prescription drugs and
medical supplies. The Commission was directed to examine the need for a bulk purchasing
mechanism, and to determine if there would be financial benefits and potential savings to private
citizens, insurance carriers, self-insured employee health benefit plans and publicly funded health
coverage. The charge also required the Commission to evaluate the potential impact of bulk
purchasing on the State's economy and on pharmacies, hospitals and other health care facilities
within the State. Resolve 1999, chapter 75, included as Appendix A, sets out the complete
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charge to the Commission.

Early in its deliberations, the Commission determined that a broader focus was necessary,
and that more ideas need to be explored in order to improve access to prescription drugs. It
therefore interpreted its charge as a starting point, and used its meetings to examine additional
approaches. The Commission also determined that its top priority was making prescription drugs
more affordable, and therefore did not address durable medical equipment and medical supplies.

C. Study process

The Commission to Study Bulk Purchasing of Prescription Drugs and Medical Supplies
consisted of 12 members, appointed by the Senate President, the Speaker of the House of
Representatives and the Governor. In addition to six legislators representing both major political
parties, the membership included the following persons: a member of a professional organization
representing pharmaceutical manufacturers; a member of a statewide organization representing
health care carriers regulated under Titles 24 and 24-A of the Maine Revised Statutes; a member
from a statewide organization representing hospitals; a member of a statewide organization
representing pharmacies; a member from a statewide organization representing pharmaceutical
wholesalers; and the Director of the Bureau of Medical Services within the Department of Human
Services, or the Director’s designee. A list of the members is included as Appendix B.

The Commission met four times, as authorized by the enabling legislation, in October and
November 1999 at the State House in Augusta.

Interested parties attended the meetings,

contributed ideas and participated in the Commission’s discussion. The Commission members
themselves brought an exceptional combination of personal and professional knowledge and
experience, which allowed the discussion to start at a very high level and to progress from there.

The Commission examined the benefits and costs of the State’s entering into the
prescription drug market as a bulk purchaser. The discussion covered the following elements that
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the State would have to include in its bulk purchasing distribution system: The ability to deliver
prescription drugs to pharmacies throughout the state within hours of ordering; the ability to
stock a large number of different drugs, including branded and generic; the storage requirements
for some drugs, such as refrigeration; a large investment in technology; and the ability to track
drugs throughout the distribution system to handle recalls or other problems.

The existing

distribution system contains all these elements; the State bulk purchasing program would have to
duplicate each element.

Another significant cost identified early in the discussion is the

detrimental effect that such action may have on Maine businesses that are currently part of the
wholesale and retail prescription drug business. For these reasons, the Commission agreed that it
would also look beyond bulk purchasing to identify any other actions that would help the
Legislature address the underlying problem of high prescription drug costs for those without any
prescription drug coverage. The members and interested parties made additional suggestions.
The Commission’s recommendations are included in Part III of this report.
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II

Background

A. Prescription drugs

Prescription drugs are an integral component of today’s health care system. Medications
can be more cost-effective and less invasive than other forms of treatment, and

they play

important roles in the entire range of treatment, from saving lives to maintaining productive lives
and lifestyles. Use of medications often results in lower overall health care costs for conditions
such as asthma, AIDS, diabetes, heart disease, osteoporosis and stroke1. Taking prescription
drugs does not eliminate visits to the health care provider – physicians and other prescribers still
must ensure that the dosage is correct, determine whether the medication is having the desired
effect and monitor the patient’s condition and progress – but the resulting improvements they
produce are significant.

Health care spending has been on the increase, and many studies have been undertaken to
identify trends and factors. Just as prescription drugs are an important component in providing
health care, they play an important role in costs, too. A study published by the National Institute
for Health Care Management Foundation reported that total national health expenditures
experienced an average annual percentage growth of 5.5% from 1992 to 1997. Prescription drug
expenditures over the same period increased an average of 11.1% annually. This difference
resulted in prescription drugs becoming a larger factor in total national health expenditures,
increasing from 5.6% in 1992 to 7.2% of expenditures in 19972.

In Maine, Medicaid

expenditures, after rebates, for outpatient prescription drugs increased by 9.5% from state fiscal
year 1996-1997 to 1997-1998, and by 20.3% from 1997-1998 to 1998-19993.

The

pharmaceutical industry figures paint a less stark picture: The Pharmaceutical Reseacrh and
1

PhRMA, Backgrounder: The Myth of “Rising Drug Prices” Exposed, January 14, 1999, page 1.

2

National Institute for Health Care Management, Factors Affecting the Growth of Prescription Drug Expenditures,
Barents Group LLC, July 1999, page 1.
3

Spreadsheet from Christopher Nolan, Department of Human Services, November 29, 1999, included as Appendix
C.
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Manufacturers of America (PhRMA) reports that the percentage of Gross Domestic Product
(GDP) spent on prescription drugs has stayed at about one-half of one percent for the past 30
years, while the portion of GDP devoted to health care has increased from 7.4 % in 1970 to an
estimated 14.4% in 19964.

A change in regulatory restrictions on print and television advertising has resulted in many
new direct-to-consumer (DTC) advertising campaigns. About $1.3 billion was spent on DTC
advertising in 19985. The ten drugs most heavily advertised to consumers in 1998 accounted for
$9.3 billion or about 22 percent of the total increase in drug spending between 1993 and 1998.

A portion of the increased expenditures on pharmaceuticals is related to rising drug prices.
Several studies have pointed out large price increases for individual items6. One study attributes
64% of the increased spending to higher per prescription prices7; another study calculated that the
prices for the 50 prescription drugs most frequently used by the elderly rose more than four times
the rate of inflation during calendar year 19988. Maine Medicaid prescription drug expenditures
per prescription increased 22.8% from state fiscal year 1996-1997 to 1997-19989. An additional
reason that the average price per prescription has gone up so dramatically is the introduction of
expensive new drugs that replace lower-cost existing medications. On average, the new drugs
cost more than twice as much as older drugs10.
4

PhRMA, Backgrounder: Prescription Drug Prices and Profits, page 4.

5

National Institute for Health Care Management, Factors Affecting the Growth of Prescription Drug Expenditures,
Barents Group LLC, July 1999, page 12.
6

Families USA, Hard to Swallow, Rising Drug Price’s for America’s Seniors, November 1999; National Institute
for Health Care Management, Factors Affecting the Growth of Prescription Drug Expenditures, Barents Group
LLC, July 1999; Access and Affordability Monitoring Project, Boston University School of Public Health,
Affordable Medications for Americans, Alan Sager, Ph.D., Deborah Socolar, M.P.H., July 1999.
7

National Institute for Health Care Management, Factors Affecting the Growth of Prescription Drug Expenditures,
Barents Group LLC, July 1999, page 15.
8

Families USA, Hard to Swallow, Rising Drug Price’s for America’s Seniors, November 1999, page 2.

9

Spreadsheet from Christopher Nolan, Department of Human Services, November 29, 1999, included as Appendix
C.
10

National Institute for Health Care Management, Factors Affecting the Growth of Prescription Drug
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Rising drug expenditures are also attributable to greater drug utilization nationwide. The
number of prescriptions filled increased from 1.9 billion in 1993 to 2.5 billion in 1998, a jump of
600 million prescriptions11. According to IMS Health, an organization that tracks pharmaceutical
sales at the retail level, a large portion of the increase in expenditures for prescription drugs in
1998 is accounted for by the increased use of drugs, as well as the fact that doctors are more
frequently prescribing newer, innovative and sometimes more costly medicines. For some leading
therapeutic categories, the total utilization rate more than doubled between 1993 and 1998. For
example, the number of prescriptions filled for oral antihistamines increased by 500% to 41
million prescriptions; the number filled for cholesterol-lowering medications increased by 162% to
68 million prescriptions, and for antidepressants, the number increased by 111% to 120 million.
Also increasing is the number of prescriptions written and filled per person; therapies often
include more than one medication to treat a particular illness or condition. Maine Medicaid
outpatient prescription drug figures show a per person increase in the number of prescriptions of
5.6% from state fiscal year 1996-1997 to 1998-199912.

In addition, more drugs are being introduced to treat conditions that formerly were not
treatable by medication. The increase in use of drugs rather than surgery or to prevent heart
attacks and strokes, for example, results in greater expenditures for drugs, but greatly lowers or
eliminates expenditures in other categories of health care. A recent study showed that a new
medicine to prevent osteoporosis costs just $3,000 over 15 years – instead of $41,000 for hip
replacement surgery13. New therapies are changing the quality of life, reducing the length of
hospital stays and decreasing other, often more expensive and more invasive, components of
medical care.

Expenditures, Barents Group LLC, July 1999, page 18.
11

National Institute for Health Care Management, Factors Affecting the Growth of Prescription Drug
Expenditures, Barents Group LLC, July 1999, page 21.
12

Spreadsheet from Christopher Nolan, Department of Human Services, November 29, 1999, included as
Appendix C.
13

PhRMA, Backgrounder: Prescription Drug Prices and Profits, page 4.
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B. Methods of paying for prescription drugs available in Maine

There are three ways Maine residents obtain their prescription drugs.

Many have

prescription drug coverage as part of a comprehensive health benefit program. These consist of
both private and public programs, including private insurance programs, Medicaid and Cub Care,
the state children’s health care program established under Title XXI of the federal Social Security
Act. Second, some receive benefits under stand-alone state drug benefit programs. The Elderly
Low-Cost Drug Program is one such program, under which the participant receives drug benefits,
but no other health benefits. Despite the availability of these programs, many consumers have no
prescription drug insurance and do not qualify for any of the federal or state public programs that
provide prescription drug benefits; they pay cash for their medications, or they do without.
Although the Department of Human Services is in the process of determining a more accurate
figure for who is not covered by any form of prescription drug program, there are estimates that
as many as 20-25% of all Mainers fall into this category. Many of these consumers are elderly, on
fixed incomes, or both, and, because no one negotiates price discounts for them, they usually pay
the highest prices for prescription drugs.

Prescription benefit managers negotiate with

manufacturers for better prices for their insureds; the federal government obtains lower prices for
huge purchasers such as the Department of Defense and the Veterans Administration; the federal
government also mandates manufacturers’ rebates for the Medicaid program through a statutory
formula; the federal Office of Drug Pricing negotiates reduced prices for certain federal health
care grant recipients. Some studies indicate that as the larger purchasers negotiate lower and
lower prices, the costs of providing those lower prices are shifted to the cash-paying consumers,
who usually end up paying the highest prices of all.

Perhaps the hardest hit are the elderly. Per capita, persons over 62 use more prescription
drugs than any other segment of the population. They rely on medication to keep them out of
hospitals and nursing homes, help them maintain their health and continue to be participating,
productive members of the community. Many people do not have prescription drug benefits once
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they retire, ironically the time in their lives when they could benefit most from the coverage.
Although it is at the top of the list for Medicare reform, there is currently no prescription drug
benefit for outpatients under Medicare. Medicare recipients who want prescription drug coverage
have the option of purchasing on the private market different “Medi-gap” policies which may be
cost prohibitive.

It has been reported that, for some, although there is currently limited

information about the number of such people in Maine, the cost of their prescription medications
is so high that they must choose between paying their rent and filling their prescription.
According to testimony presented at a joint public hearing of the Joint Standing Committees on
Health and Human Services and Taxation on March 3, 1999, some elderly couples often have to
choose whose prescription will be filled, because their limited income will not pay for all the
medications they both need.

Some uninsureds have taken the step of traveling to where lower prescription drug prices
are paid by the uninsured consumer. On more than one occasion, senior citizens in Maine have
boarded buses for Quebec, where prices for prescription drugs that are on the Quebec formulary
are as low as two-thirds the cost in the United States. One such trip was featured on 60 Minutes
in October 1999.

Individual research-based pharmaceutical manufacturers have developed prescription drug
patient assistance programs.

Each manufacturer designs and administers its own program.

Through these programs manufacturers provide prescription medicines free of charge to
physicians whose patients might not otherwise have access to necessary medicines. The duration
of benefits varies by drug and manufacturer. PhRMA publishes a directory of these programs,
and includes instructions on how to access the benefits. In 1998, PhRMA member company
programs provided 2.8 million prescriptions for 1.5 million patients in the United States. The
wholesale value of those drugs totaled $500 million. A more coordinated approach to these
programs, recognizing anti-trust restrictions, could greatly benefit consumers; a single website on
the Internet maintained by an independent entity may be extremely useful.

Maine law authorizes the voluntary establishment of private purchasing alliances. An
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alliance is a nonprofit corporation licensed under the Insurance Code to provide health insurance
to its members through multiple unaffiliated carriers. Alliances are authorized to set their own
standards for membership in the alliance. These entities are designed to provide additional
options for the purchase of insurance by small employers. Although the law became effective in
July 1996 and the rules governing alliances were finally adopted in March 1997, there are no
licensed purchasing alliances in the State.

Employers and others may want to explore the

establishment of private purchasing alliances to provide prescription drug coverage for their
employees.

C. Maine prescription drug programs

Maine has established a number of programs under which participants receive prescription
medication for no charge, for a co-pay or at a reduced price.

1.

Medicaid.

(22 MRSA §3174-G, subsection 1) In Maine, the Medicaid

program is the largest payor for prescription medication, as well as for hospitalization and care by
physicians and other providers. To qualify for Medicaid, a person must meet income criteria and
be a member of a category covered by Medicaid, referred to as being “categorically eligible.” In
Maine Medicaid categories include:
a. Children up to age 12 months and pregnant women - both at family income levels up to
185% of the federal poverty level (fpl) ;
b. The elderly and the disabled - both at family incomes up to 100% fpl;
c. Children ages one through 18 - at family incomes up to 150% fpl; and
d.

Families qualified to receive benefits under the Temporary Assistance to Needy

Families (TANF) program under 22 MRSA chapter 1053-B.

The income limits have some flexibility for people who have high medical expenses,
known as “spend down” eligibility. There are no co-pays for children. Adults may have a
variable co-pay of up to $3 on some services.
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government.

2. Cub Care. (22 MRSA §3174-T) The Cub Care program provides health
coverage for children ages one year through 19, at family incomes up to 200% of the federal
poverty level.

The income limit was increased from 185% on October 1, 1999 under the

Commissioner’s powers to increase or decrease the income limit to maximize coverage within the
funding limits of the program under 22 MRSA §3174-T, subsection 2, paragraph A. It is
anticipated that the increased coverage will be provided within the original Cub Care state and
federal budget amounts during state fiscal year 1999-2000.

Beginning July 1, 2000 the income limit is raised to 200% of the federal poverty level (fpl)
by statute, PL 1999, Chapter 401, Part QQ. Additional funding of $466,796 is provided from the
Fund for a Healthy Maine (the national tobacco settlement money) for the cost of benefits. Also
allocated from the Fund for a Healthy Maine during state fiscal year 2000-2001 is $29,587 for a
staff person in the Department of Human Services (DHS) for Cub Care administration. Matching
federal funds were allocated for both accounts.

Children age birth through age 12 months are covered under the Medicaid program,
because persons eligible for Medicaid are required by federal law to be covered under that
program. This creates a bit of a gap between the pregnant women and children to age 12 months,
with incomes to 185% fpl, who are on Medicaid and the Cub Care children at 200% fpl. DHS is
considering the challenge presented by this disparity.

The Cub Care program provides full health care benefits, including prescription medicines
and supplies, exactly the same as the Medicaid program. There are no co-pays.

Families are required to pay contributions for coverage (premiums), depending on family
income, calculated at 5% of benefit cost for families at 150-160% fpl, 10% of benefit cost for
families at 160-170% fpl, and 15% of benefit cost for families at 170-185% fpl. There is a
maximum (the base times 2) in each category of income. The benefit cost is an average for the
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program, currently around $1200 per year per child. There is no statutory premium figure for
children 185 to 200% fpl; DHS will presumably charge them the same as children with family
incomes 170-185% fpl.

3. Elderly Low-Cost Drug Program. (22 MRSA 254, as amended by LD 617,
PL 1999, chapter 401, Part KKK, as further amended by LD 2255, PL 1999, chapter 531, Part F)

a. The basic component. The basic component of the Elderly Low-Cost Drug Program
(ELCDP) provides assistance with payment for prescription medicines for adults ages 62 and over
and disabled adults for certain specified chronic medical conditions. The conditions covered
include cardiac and high blood pressure, diabetes, arthritis, anticoagulation, hyperlipidemia,
osteoporosis, chronic obstructive pulmonary disease and asthma, incontinence, thyroid diseases,
glaucoma, Parkinson’s disease, multiple sclerosis and amytrophic lateral sclerosis (Lou Gehrig’s
disease).

Beginning August 1, 1999, the existing ELCDP was revamped to increase the income
level and designate it as the basic component of the ELCDP. The income level for the ELCDP
increased from roughly 131% of the federal poverty level to 185%. Before August 1, 1999, the
income level was determined by reference to the Maine Residents Property Tax Program (the
“circuit breaker” program) and was not expressed as a percentage of the federal poverty level.
Persons who pay more than 40% of their income for unreimbursed prescription drugs are eligible
for the basic component up to an additional 25% of the applicable income levels. The co-pay is
$2 or 20%, whichever is greater.

b. The supplemental component. The “supplemental component of the program” came
into effect August 1, 1999. The supplemental component of the program covers all prescription
drugs and medications provided under the Medicaid program with certain exceptions. Under the
supplemental component of the program participating manufacturers will discount their drug
prices by the same amount as the Medicaid discount.
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DHS will pay $2 toward the cost of the prescription.

The consumer will pay the

remainder. The effect of the DHS $2 co-pay and the Medicaid level discount will be a discount to
the consumer that is estimated to be about 20% off current prices paid by those without drug
coverage.

No state funds were allocated or appropriated for the supplemental component of the
program. It is intended to be self-sufficient, operating on the discounts and $2 DHS co-pay.

4. Maine Resident Low-Cost Prescription Drug Program. (22 MRSA §254-B,
from LD 2082, Public Law 1999, chapter 431) Beginning February 1, 2000, or as soon thereafter
as possible, a new program is scheduled to take effect:

the Maine Resident Low-Cost

Prescription Drug Program, MRLCPDP. Under this program manufacturers who choose to
participate voluntarily pay rebates to DHS. DHS plans to set the voluntary rebates approximately
the same amount as the Medicaid rebates (around 18-20% at present).

According to DHS, a

manufacturer who chooses to participate must participate for all drugs sold in the state.

When filling a prescription, the consumer picks whichever participating pharmacy he or
she wishes and may perhaps have a choice of manufacturer. The pharmacist discounts the
prescription from the pharmacy’s normal price by the discount amount established by DHS
(roughly the rebate amount). Except for applying the mandatory discount to drugs provided by a
participating manufacturer, the pharmacy is free to set its own prices, so the consumer’s price for
a drug produced by a participating manufacturer may vary from pharmacy to pharmacy.

If the drug purchased is one for which a discount has been applied, the pharmacy notifies
DHS and DHS pays the discount amount to the pharmacy weekly or biweekly. To qualify for
MRLCPDP the consumer must be a Maine resident and have no 3rd party prescription drug
coverage. There is no enrollment procedure or identification card. Eligibility is established by the
pharmacist when the consumer fills the prescription.

DHS is preparing rules that should address many of the concerns raised during the
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hearings before passage of LD 2082 and reiterated to the Commission. Those concerns include:
•

The method by which DHS will calculate the discount per drug without revealing the
amount of the Medicaid rebate paid for that drug;

•

The way or ways by which pharmacies will be expected to determine whether an
individual is a Maine resident and has no prescription drug coverage;

•

How Maine residents will know which companies are participating in the program, and
which drugs are produced by those companies;

•

How Maine residents will know that the discount is paid by the manufacturer, and
does not come from the State; and

•

How DHS will implement the statutory requirement that the rules “promote the use of
efficacious and lower-cost drugs.”

MRLCPDP is self-funded by the voluntary rebates paid by participating manufacturers.
There is no state appropriation to support this program. There are allocations of $2,500,000 in
state fiscal year 1999-2000 and $10,000,000 in 2000-2001 from the rebate amounts paid in to
DHS by the participating manufacturers.

The MRLCPDP will take effect only after DHS completes the rule-making process, which
includes a public hearing on the proposed rules. Once the rules are provisionally adopted, they
must be submitted to the Legislature for review and approval as “major substantive” rules.

5. Medicaid waiver drug program. (22 MRSA §3174-G, subsection 1-A, from
LD 617, Public Law 1999, chapter 401, Part KKK, as amended by LD 2255, Public Law 1999,
chapter 531, Part F) The statute directs DHS to apply for a Medicaid waiver to provide Medicaid
prescription drug benefits as follows.
•

Qualified persons ages 62 and over and disabled persons ages 19 and over are eligible for
benefits. The family income limitation for both sets of persons is 185% fpl. Coverage
under the Medicaid waiver drug program is contingent upon sufficient funds being
appropriated and allocated to cover costs. If funding is insufficient, the income limit is to
be decreased.
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•

The full range of drugs provided in the Medicaid program must be provided.

•

There is no asset limitation.

•

Co-payments are comparable to Medicaid co-payments.

•

Coverage is required to begin July 1, 2000 or as soon thereafter as possible.

Funding is governed by 22 MRSA §3174-G, subsection 1-B and is to be provided by a
combination of funds:
a. Funding appropriated to the Elderly Low-Cost Drug Program and any rebates paid
under that program,
b. Funding of at least $5,000,000 in state fiscal year 2000-2001 from the Fund for a
Healthy Maine, and
c. Allocated federal matching funds for state fiscal year 2000-2001 of $23,804,694.

Establishment of this Medicaid waiver drug program is contingent on approval of the
waiver by the federal Health Care Financing Administration (HCFA).

The federal poverty levels for 1999 are:

100%

150%

185%

200%

Family of one

$8240

$12,360

$15,244

$16,480

Family of two

$11,060

$16,590

$20,461

$22,120

D. Other prescription drug programs and proposals

1. Federal Office of Drug Pricing. The Office of Drug Pricing (ODP), part of
the Bureau of Primary Health Care within the U.S. Department of Health and Human Services, is
responsible for the implementation and management of Section 340B of the Public Health Service
Act (enacted as part of the Veterans Health Care Act of 1992, PL 102-585). Section 340B
provides that a manufacturer who sells covered outpatient drugs to eligible entities must sign a
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pharmaceutical pricing agreement with the Secretary of Health and Human Services in which the
manufacturer agrees to charge a price for covered outpatient drugs that will not exceed an
amount determined under a statutory formula. Although the price calculation is the same as the
Medicaid rebate calculation, the purchasers under the 340B program pay the reduced cost
upfront, rather than first paying full price and receiving a rebate later. The costs of drugs under
the 340B program are generally, but not always, slightly higher than the Federal Supply Schedule.

An entity is eligible to take advantage of the 340B program prices if it falls within the
program’s definition of “covered entity.” “Covered entities” are defined in the statute as follows.
°

Federally-qualified health centers

°

Entities receiving grants for health services for residents of public housing

°

Qualified family planning projects

°

HIV early intervention programs

°

State-operated AIDS drug purchasing assistance programs

°

Qualified black lung clinics

°

Qualified comprehensive hemophilia diagnostic treatment centers

°

Qualified Native Hawaiian Health Centers

°

Qualified urban Indian organizations receiving funds under the Indian Health Care
Improvement Act

°

Qualified HIV health care services programs

°

Entities receiving funds for treatment of sexually transmitted diseases or tuberculosis

°

Qualified “subsection (d) hospitals”

Certain restrictions apply to the covered entities and their practices in order to maintain
eligibility under the ODP program. The "Entity Guidelines" published in the Federal Register
prohibit covered entities from reselling or otherwise transferring outpatient drugs purchased at the
statutory discount to an individual who is not a patient of the covered entity. The ODP definition
of a patient (see Federal Register Notice, "Patient and Entity Eligibility", October
24, 1996, p.55157, Item (C)) states: "An individual is a "patient" of a covered entity (with the
exception of State-operated or funded AIDS drug purchasing assistance programs) only if: (1) the
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covered entity has established a relationship with the individual, such that the covered entity
maintains records of the individual's health care: and (2) the individual receives health care
services from a health care professional who is either employed by the covered entity or provides
health care under contractual or other arrangements (e.g. referral for consultation) such that
responsibility for the care provided remains for the covered entity; and (3) the individual receives
a health care service or range of services from the covered entity which is consistent with the
service or range of services for which grant funding or Federally-qualified health center look-alike
status has been provided to the entity. Disproportionate share hospitals are exempt from this
requirement. An individual will not be considered a "patient" of the entity for purposes of 340B if
the only health care service received by the individual from the covered entity is the dispensing of
a drug or drugs for subsequent self-administration or administration in the home setting. An
individual registered in a State operated or funded AIDS drug purchasing assistance program
receiving financial assistance under title XXVI of the PHS Act will be considered a "patient" of
the covered entity for purposes of this definition if so registered as eligible for the State program."

Entities in Maine listed in the ODP’s database as participating the ODP programs are
listed in Appendix E.

2. Canadian pricing

Several studies have pointed out that prescription drug prices in

Canada, as well as in other countries, are significantly lower than U.S. drug prices for the same
medication14. The Canadian health department -- Health Canada -- regulates the price of patented
drugs. Once a new prescription drug is approved for market by the Therapeutics Products
Program of the Health Protection Branch of Health Canada, the maximum price the manufacturer
can charge is established by the Patented Medicine Prices Review Board15. The mandate of the
PMPRB is to ensure that the prices of patented medicines are not excessive. If the PMPRB
determines that a manufacturer has charged excessive prices, it can recover double the excess
revenues from the manufacturer. The PMPRB follows fairly extensive guidelines in establishing
14

Congressional Research Service, Prescription Drug Price Comparisons: The United States, Canada and Mexico,
David Cantor, January 23, 1998.
15

Patented Medicine Prices Review Board, Health Canada, Compendium of Guidelines, Polices and Procedures,

16

COMMISSION TO STUDY BULK PURCHASING OF PRESCRIPTION DRUGS AND MEDICAL SUPPLIES

prices and in determining whether excessive prices have been charged. In general, prices paid to
the manufacturer are tied to the prices of other drugs in the same therapeutic class and the range
of prices paid in seven other countries: France, Germany, Italy, Sweden, Switzerland, the United
States and the United Kingdom. Price increases are tied to the Consumer Price Index.

After the PMPRB establishes the maximum price, each Province negotiates with the
manufacturer for the price it will pay for the drug. As provincial plans cover about 44% of all
prescription drug sales in Canada, each Province carries significant weight in the negotiations.
Private insurers can also negotiate with the manufacturers for the best price under their plans, but
in practice that price is the same as the price established for the provincial plans.

3.

Other states’ approaches.

The Commission looked at how other states have

approached the increasing lack of affordability of prescription drugs. Nevada has enacted a
program to pay up to $480 of prescription drug insurance premiums for seniors without such
coverage. New Hampshire has established a plan for seniors which is administered by a private
entity and under which the private entity negotiates lower prices with manufacturers. Missouri
established a state annual income tax credit of up to $750 for pharmaceutical costs incurred by
qualified seniors and disabled veterans. California recently passed legislation directing pharmacies
that participate in the California Medicaid program to also offer a discount to all Medicare
beneficiaries16.

www.pmprb-cepmb.gc.ca/comp-in-e.html.
16
National Conference of State Legislatures, “Making Medicines Affordable,” Richard Cauchi, State Legislatures,
December 1999, pp. 10-11.
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III

Findings and Recommendations

A. Findings. The Commission makes the following findings.

1. Prescription medications are essential to the life and health of Maine
residents, while remaining unaffordable to some, particularly the elderly.

2.

About 25% of Maine residents are on their own when purchasing

prescription medicines because they do not have private medication
insurance, do not qualify for state or federal assistance programs, cannot
afford to purchase drug coverage insurance, or, lastly, although they can
afford them, choose not to purchase a drug insurance program.

3. Maine residents who have no prescription drug coverage pay the full
retail price for prescription drugs. Those who are covered by a prescription
drug program benefit from the volume purchases of prescription medications
made by their health insurance provider, the state Medicaid Program, the
federal Office of Drug Pricing, private Pharmacy Benefit Managers or other
private health care providers, and usually pay a co-pay on a negotiated
discounted price.

4. Although large volume purchasers can often negotiate lower prescription
drug costs, and competition at the retail level may result in savings to the
consumer, there are many other factors which also affect the cost of
prescription drugs.

5.

The State has considerable clout in negotiating volume discounts, as

indicated by the establishment both components of the ELCDP, the Maine
Medicaid Program and General Assistance. Without detailed investigation,
the implementation of a separate distribution system appears very costly,
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which may negate any savings that the State could achieve through bulk
purchasing.
6. The 119th Maine Legislature approved the Maine Residents Low-Cost
Drug Program, which is scheduled to begin in 2000, and significantly
expanded the Elderly Low-Cost Drug Program.

7. Maine prescribers, pharmacists and other health care professionals want
to help their patients acquire effective prescription medications at reasonable
prices.

8. The affordability of prescription drugs is a national issue, not unique to
Maine.

B.

Recommendations.

The following are unanimous recommendations of the

Commission.

1.

The Commission recommends that the State should not at this time

pursue bulk purchasing of prescription drugs as a separate program.

2. The Commission recommends that the State expand educational outreach
to inform Maine citizens about the many State, Federal and private
programs available to reduce prescription costs.

3. The Commission recommends that the State investigate the possibility of
joining with other states, especially in local or regional affiliations, to lower
prescription drug costs to consumers.

4. Recognizing that the Legislature and the Department of Human Services
anticipate that the Maine Residents Low-Cost Drug Program will reduce
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prescription drug costs to consumers, the Commission recommends that the
State move forward as rapidly as possible with the rule-making and
legislative process to implement the program.

5. The Commission recommends that the availability of access to reducedcost prescription drugs through the federal Office of Drug Pricing be
explored more thoroughly to determine whether prescription drugs at a
lower price can be made more available to programs providing services to
Maine residents.

6. The Commission recommends that the State encourage a public-private
partnership to generate, maintain and distribute a simple and coordinated
therapeutic and pricing guideline for physicians and other prescribers.

7. The Commission recommends that the State encourage public-private
partnerships for expanded purchasing volume, thereby increasing ability to
purchase prescription drugs at lower prices.

8. The Commission recommends that the Department of Human Services
continue to pursue the Medicaid waiver with the Health Care Financing
Administration.
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RESOLVES
First Regular Session of the 119th

CHAPTER 75
H.P. 144 - L.D. 206
Resolve, to Establish the Commission to Study Bulk Purchasing of Prescription Drugs and
Medical Supplies
Emergency preamble. Whereas, Acts and resolves of the Legislature do not become effective until 90 days
after adjournment unless enacted as emergencies; and
Whereas, a comprehensive study of bulk purchasing of prescription drugs and medical supplies is needed to
determine whether bulk purchasing could be used to provide Maine residents access to affordable
prescription drugs and medical supplies, such a study to be undertaken during the summer and fall of 1999;
and
Whereas, in the judgment of the Legislature, these facts create an emergency within the meaning of the
Constitution of Maine and require the following legislation as immediately necessary for the preservation of
the public peace, health and safety; now, therefore, be it
Sec. 1. Commission established. Resolved: That there is established the Commission to Study Bulk
Purchasing of Prescription Drugs and Medical Supplies, referred to in this resolve as the "commission";
and be it further
Sec. 2. Membership. Resolved: That the commission consists of 12 members appointed as follows:
1. The President of the Senate shall appoint 5 members as follows:
A. Two Senators, one from each major political party. The first-named Senator is the Senate chair;
B. One person from a professional organization representing pharmaceutical manufacturers;
C. One person from a statewide organization representing health care carriers regulated under the
Maine Revised Statutes, Titles 24 and 24-A; and
D. One person from a statewide organization representing hospitals;
2. The Speaker of the House of Representatives shall appoint 5 members as follows:
A. Four Representatives, 2 from each major political party. The first-named Representative is the House
chair; and
B. One person from a statewide organization representing pharmacies; and
3. The Governor shall appoint 2 members as follows:
A. The Director of the Bureau of Medical Services within the Department of Human Services or the
director's designee; and
B. One person from a statewide organization representing pharmaceutical wholesalers; and be it further

Sec. 3. Appointments; meetings. Resolved: That all appointments must be made no later than 30 days
following the effective date of this resolve. The appointing authorities shall notify the Executive Director of
the
Legislative Council upon making their appointments. When the appointment of all members is complete,
the chairs
shall call and convene the first meeting of the commission no later than July 30, 1999; and be it further
Sec. 4. Duties. Resolved: That the commission shall study bulk purchasing of prescription drugs and
medical supplies. The commission shall study the need for a bulk purchasing mechanism and the financial
benefits
and potential savings to private citizens, insurance carriers, self-insured employee health benefit plans and
publicly
funded health coverage. The commission shall evaluate the potential impact of bulk purchasing on the
State's
economy and on pharmacies, hospitals and other health care facilities within the State. In its report, the
commission shall propose a plan for bulk purchasing that represents the best judgment of a majority of the
members of the commission for a bulk purchasing mechanism for the State.
In examining the issue of bulk purchasing of prescription drugs and medical supplies, the commission
may
examine bulk purchasing mechanisms in use in other states and countries and shall consult with interested
parties
representing a broad range of views.
The commission is authorized to meet as necessary to complete its work, up to a maximum of 4
meetings of
the commission; and be it further
Sec. 5. Staff assistance. Resolved: That the commission may request staffing and clerical assistance
from
the Legislative Council; and be it further
Sec. 6. Compensation. Resolved: That the commission members who are Legislators are entitled to
receive
the legislative per diem, as defined in the Maine Revised Statutes, Title 3, section 2, for each day's
attendance at
meetings of the commission and are entitled to reimbursement for travel and other necessary expenses,
upon
application to the Legislative Council. The Executive Director of the Legislative Council shall administer
the
commission's budget; and be it further
Sec. 7. Report. Resolved: That the commission shall submit its report with any accompanying
legislation to
the Joint Standing Committee on Health and Human Services by December 1, 1999. If the commission
requires a
limited extension of time to conclude its work and make its report, it may apply to the Legislative Council,
which

may grant the extension. Upon submission of its required reports, the work of the commission terminates;
and be
it further
Sec. 8. Appropriation. Resolved: That the following funds are appropriated from the General Fund to
carry
out the purposes of this resolve.
1999-00
LEGISLATURE
Commission to Study Bulk Purchasing of Prescription Drugs and Medical Supplies
Personal Services $1,320
All Other 1,700
Provides funds for the per diem and expenses of legislative members for 4 meetings of the Commission
to
Study Bulk Purchasing of Prescription Drugs and Medical Supplies and to print the required report.
LEGISLATURE ____________
TOTAL $3,020
Emergency clause. In view of the emergency cited in the preamble, this resolve takes effect when
approved.
Effective June 17, 1999.

Commission to Study Bulk Purchasing of Prescription Drugs and Medical Supplies
Resolve 1999, Chapter 75
Appointments by the Governor
•

Robert E. Carroll, Jr., R.Ph.
Department of Professional and Financial Regulation

•

William Griffin
Bindley Western, Goold Division

Appointments by the President of the Senate
•

Senator Peggy A Pendleton, R.N., Chair
Senate District 31 (Cumberland County)

•

Senator I. Joel Abromson
Senate District 27 (Cumberland County)

•

Bruce Daniels, R.Ph., MBA
MaineGeneral Medical Center
(representing a statewide organization representing hospitals)

•

David L. Massanari, M.D.
Harvard Pilgrim Health Care
(representing a statewide organization representing health care carriers)

•

Marjorie E. Powell, Esq.
Pharmaceutical Research and Manufacturers of America (PhRMA)
(representing a professional organization representing pharmaceutical manufacturers)

Appointments by the Speaker of the House of Representatives
•

Representative Elaine Fuller, R.N., Chair
House District 80 (Manchester)

•

Representative Joseph Bruno, R.Ph.
House District 38 (Raymond)

•

Representative David G. Lemoine
House District 20 (Old Orchard Beach)

•

Representative Christine Savage
House District 60 (Union)

•

Reginald S. Gracie, Jr., R.Ph.
Rite-Aid Corporation; Maine Pharmacy Association
(representing a statewide organization representing pharmacies)
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Medicaid Outpatient Prescription Drug Spending
SFY 97
Gross Expenditures
Drug Rebates
Net Expenditures
Drug Rebate Percentage
Number of Drug Recipients
Gross Exp Per Recipient
Net Exp Per Recipient
Number of Prescriptions
Prescriptions per Recipient
Expenditures per Prescription

SFY 98

$98,964,628
-$17,206,484
$81,758,144

$109,697,688
-$20,206,046
$89,491,642

17.4%

18.4%

141,220

144,205

Chg
10.8%
17.4%
9.5%

SFY 99
$135,493,928
-$27,957,863
$107,536,065

Chg
23.5%
38.4%
20.2%

20.6%
2.1%

148,654

3.1%

$700.78
$578.94

$760.71
$620.59

8.6%
7.2%

$911.47
$723.40

19.8%
16.6%

2,793,666
19.8
$35.42

2,870,422
19.9
$38.22

2.7%
0.6%
7.9%

3,114,155
20.9
$43.51

8.5%
5.2%
13.8%

Federal Office of Drug Pricing

Entities in Maine listed in the Office of Drug Pricing’s database as participating the ODP
programs include:
°

Bucksport Regional Health Center

°

Regional Medical Center at Lubec

°

Health Care for Portland’s Homeless Project

°

Tri-County Health Services, Farmington Family Planning Clinic

°

Rumford Family Planning Clinic

°

Machias Family Planning Clinic

°

Health 1st Family Planning Clinic (Fort Kent)

°

Midcoast Clinic (Belfast)

°

Skowhegan Family Planning Clinic, Michelle Boulette Center

°

Planned Parenthood of Northern New England (Portland)

°

Planned Parenthood of Northern New England (Biddeford))

°

Planned Parenthood of Northern New England (Brunswick)

°

Planned Parenthood of Northern New England (Sanford)

°

Portland Division of Public Health

°

Maine Department of Human Services, Bureau of Health, HIV/STD Program

°

Penquis health Services (Bangor)

°

Dexter Family Planning Clinic

°

Guilford Family Planning Clinic

°

Lincoln Family Planning Clinic

°

City of Portland, Public Health Division

°

Millinocket Family Planning Clinic

°

Milo Family Planning Clinic

°

Sacopee Valley Health Center, Family Planning Clinic

°

Auburn Family Planning Clinic

°

Norway Family Planning Clinic
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°

Calais Family Planning Clinic

°

Arthur Jewell Community Health Center, Reynolds Road Brooks)

°

Health 1st, Houlton Family Planning Clinic

°

Health 1st Family Planning (Madawaska)

°

Midcoast Family Planning Clinic (Damariscotta)

°

Midcoast Family Planning Clinic (Rockland)

°

Health 1st, Patten Family Planning

°

KVCAP Family Planning (Jackman)

°

Pittsfield Family Planning Clinic

°

KVCAP family Planning (Hinckley)

°

Health 1st Family Planning Program (Presque Isle)

°

Kennebec Family Planning (Augusta)

°

Downeast Health Services, Inc., Family Planning Clinic (Ellsworth)

°

Kennebec Valley Community Action (Waterville)

°

Penquis Community Action Program (Bangor)

°

Western Maine Community Action (East Wilton)

°

Aroostook County Action Program (Presque Isle)

°

Penobscot Bay Medical Center

°

Family Planning Association of Maine, Inc. (Augusta)

°

Maine Department of Human Services
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